New treatment aims to keep deadly childhood cancer from returning
NCT ID NCT03033303
Summary
This study tested whether a combination of immunotherapy drugs could prevent cancer from returning in children with high-risk neuroblastoma who had achieved their first remission. The treatment involved Hu3F8 antibodies combined with GM-CSF and isotretinoin, aiming to help the immune system recognize and attack any remaining cancer cells. The main goal was to see if this approach could keep patients cancer-free for at least two years after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.